BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166)
China
· Delayed Price · Currency is CNY 30.20
+0.54 (1.82%)
Jan 6, 2025, 4:00 PM CST
BrightGene Bio-Medical Technology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | 188.08 | 202.47 | 239.62 | 243.95 | 169.88 | 111.08 | Upgrade
|
| Depreciation & Amortization | 77.36 | 77.36 | 50.47 | 41.5 | 30.2 | 26.16 | Upgrade
|
| Other Amortization | 11.24 | 11.24 | 11.09 | 10.83 | 9.04 | 7.22 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.01 | -0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.75 | 1.75 | 1.57 | 0.26 | 0.27 | 7.68 | Upgrade
|
| Loss (Gain) From Sale of Investments | 12.41 | 12.41 | -3 | -10.02 | -3.59 | -3.36 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.9 | 0.9 | -2.23 | 10.11 | -0.81 | 3.96 | Upgrade
|
| Other Operating Activities | 72.33 | 37.19 | -1.08 | 8.27 | 21.75 | -1.34 | Upgrade
|
| Change in Accounts Receivable | -17.85 | -17.85 | 4.96 | -241.94 | -50.51 | -47.03 | Upgrade
|
| Change in Inventory | -85.77 | -85.77 | -94.94 | -6.25 | -75.71 | -39.94 | Upgrade
|
| Change in Accounts Payable | -23.61 | -23.61 | 130.2 | 116.92 | 47.33 | 16.77 | Upgrade
|
| Change in Other Net Operating Assets | -2.96 | -2.96 | -21.31 | 4.16 | 11.65 | -11.65 | Upgrade
|
| Operating Cash Flow | 215.53 | 194.77 | 311.26 | 176.08 | 155.43 | 61.33 | Upgrade
|
| Operating Cash Flow Growth | 5.52% | -37.43% | 76.78% | 13.28% | 153.42% | -4.15% | Upgrade
|
| Capital Expenditures | -354.5 | -403.76 | -726.73 | -909.66 | -355.27 | -89.54 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.38 | 0.48 | 0.38 | 0.05 | 0.01 | 0.69 | Upgrade
|
| Cash Acquisitions | - | - | 0.01 | -7.5 | - | - | Upgrade
|
| Investment in Securities | -208.99 | -64.24 | -153.38 | 8.64 | -218.46 | -66.67 | Upgrade
|
| Other Investing Activities | 69.57 | 31.26 | 18.24 | 18.64 | 31.79 | -0.48 | Upgrade
|
| Investing Cash Flow | -497.14 | -439.85 | -871.58 | -889.84 | -541.92 | -155.99 | Upgrade
|
| Long-Term Debt Issued | - | 678.23 | 1,646 | 882.2 | 234.89 | - | Upgrade
|
| Total Debt Issued | 714.92 | 678.23 | 1,646 | 882.2 | 234.89 | - | Upgrade
|
| Long-Term Debt Repaid | - | -560.09 | -474.12 | -210.88 | -15.06 | - | Upgrade
|
| Total Debt Repaid | -740.85 | -560.09 | -474.12 | -210.88 | -15.06 | - | Upgrade
|
| Net Debt Issued (Repaid) | -25.93 | 118.14 | 1,172 | 671.32 | 219.83 | - | Upgrade
|
| Issuance of Common Stock | - | - | 219.81 | - | - | 439.98 | Upgrade
|
| Common Dividends Paid | -133.35 | -115.01 | -100.1 | -54.3 | -35.4 | - | Upgrade
|
| Other Financing Activities | -19.55 | 58.48 | 73 | 86.7 | 1.3 | -0.23 | Upgrade
|
| Financing Cash Flow | -178.84 | 61.61 | 1,365 | 703.72 | 185.73 | 439.76 | Upgrade
|
| Foreign Exchange Rate Adjustments | 7.92 | 2.78 | 14.15 | 3.72 | -13.03 | 1.78 | Upgrade
|
| Net Cash Flow | -452.53 | -180.69 | 818.52 | -6.32 | -213.79 | 346.88 | Upgrade
|
| Free Cash Flow | -138.97 | -209 | -415.47 | -733.59 | -199.84 | -28.21 | Upgrade
|
| Free Cash Flow Margin | -11.19% | -17.72% | -40.84% | -69.71% | -25.44% | -5.61% | Upgrade
|
| Free Cash Flow Per Share | -0.33 | -0.50 | -1.01 | -1.80 | -0.48 | -0.08 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 0.23 | Upgrade
|
| Cash Income Tax Paid | 25.14 | 29.42 | -17.03 | -7.18 | -10.16 | 6.49 | Upgrade
|
| Levered Free Cash Flow | -266.47 | -321.24 | -515.42 | -785.87 | -241.66 | -66.86 | Upgrade
|
| Unlevered Free Cash Flow | -234.95 | -293.47 | -500.6 | -779.81 | -240.38 | -66.72 | Upgrade
|
| Change in Net Working Capital | 76.07 | 103.85 | -19.96 | 78.19 | 38.79 | 78.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.